Navigation Links
PAP therapy improves neurobehavioral outcomes in children with OSA
Date:2/9/2012

Treatment of childhood obstructive sleep apnea syndrome (OSAS) with positive airway pressure (PAP) therapy improves a number of important neurobehavioral outcomes, according to a new study from the The Children's Hospital of Philadelphia.

"In our study of 52 children and adolescents with OSAS, we observed significant improvements in neurobehavioral function after three months of PAP therapy," said lead author Carole L. Marcus, professor of pediatrics at the Children's Hospital of Philadelphia. "These improvements were seen despite suboptimal adherence with treatment and were observed in a heterogeneous group of children, many with underlying medical conditions and/or developmental delays."

The findings were published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

In the prospective study, 52 children (mean age 12 4 years) with OSAS, 10 of whom had significant developmental delays, underwent neurobehavioral assessments of sleepiness, behavioral problems, attention and quality of life at baseline and after three months of PAP treatment. Adherence with PAP treatment varied widely, with an average use of 170+145 minutes per night.

PAP treatment was associated with significant improvements in attention deficits, behavior, sleepiness and caregiver- and child-reported quality of life. Improvements in sleepiness scores, but not in other outcomes, were significantly correlated with adherence. Similar improvements in behavioral scores were seen in the subset of children with developmental delays. Among subjects younger than seven (mean age 4.5 1.7 years), significant improvements were seen in sleepiness and OSAS-specific quality of life.

"OSAS in children is known to be associated with behavioral disturbances and learning deficits, but the effects of PAP therapy on these deficits have not been studied," said Dr. Marcus. "Our study is the first to demonstrate that PAP therapy results in significant improvements in a range of neurobehavioral domains in these patients, including those with developmental delays."

The study had several limitations, including the lack of a placebo group, the use of reports from subjects and caregivers only, and the lack of blinding.

"The improvements we observed in daytime sleepiness, attention, internalizing behaviors and quality of life occurred despite a mean use of PAP of only three hours a night," said Dr. Marcus. "This suggests that PAP use should be encouraged in children with OSAS, even in those with suboptimal adherence, as it can lead to improvements in function that can in turn affect family, social and school function."


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Nanotube therapy takes aim at breast cancer stem cells
2. Combination drug therapy urged to battle lung cancer
3. Sanford-Burnham researchers find molecular switch that allows melanoma to resist therapy
4. Stem Cell Therapy Shows Promise for Stroke, Studies Say
5. ACCF/AATS/SCAI/STS release consensus document to help guide use of minimally invasive heart therapy
6. New target for cancer therapy identified, preclinical study shows
7. Research finds newer radiation therapy technology improves patients quality of life
8. Radiation plus chemotherapy provides long-term positive results for head and neck cancer patients
9. Brachytherapy reduced death rates in high-risk prostate cancer patients, study finds
10. Rowley to receive Japan Prize for her role in the development of targeted cancer therapy
11. Scientists report first step in strategy for cell replacement therapy in Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: